JP2013512903A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013512903A5 JP2013512903A5 JP2012542060A JP2012542060A JP2013512903A5 JP 2013512903 A5 JP2013512903 A5 JP 2013512903A5 JP 2012542060 A JP2012542060 A JP 2012542060A JP 2012542060 A JP2012542060 A JP 2012542060A JP 2013512903 A5 JP2013512903 A5 JP 2013512903A5
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- compound according
- heterocyclyl
- alkyl
- optionally
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 112
- 125000000623 heterocyclic group Chemical group 0.000 claims description 62
- 229910052717 sulfur Inorganic materials 0.000 claims description 34
- 125000001072 heteroaryl group Chemical group 0.000 claims description 33
- 229910052760 oxygen Inorganic materials 0.000 claims description 30
- 125000005842 heteroatom Chemical group 0.000 claims description 27
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 26
- 125000004404 heteroalkyl group Chemical group 0.000 claims description 24
- 125000003107 substituted aryl group Chemical group 0.000 claims description 24
- 229910052757 nitrogen Inorganic materials 0.000 claims description 22
- 125000004452 carbocyclyl group Chemical group 0.000 claims description 20
- 125000004415 heterocyclylalkyl group Chemical group 0.000 claims description 20
- 239000008194 pharmaceutical composition Substances 0.000 claims description 20
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 18
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims description 16
- 125000000217 alkyl group Chemical group 0.000 claims description 14
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims description 14
- 150000003839 salts Chemical class 0.000 claims description 14
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 claims description 12
- 210000004027 cell Anatomy 0.000 claims description 12
- 239000012453 solvate Substances 0.000 claims description 12
- 125000005884 carbocyclylalkyl group Chemical group 0.000 claims description 11
- 239000003814 drug Substances 0.000 claims description 11
- 206010028980 Neoplasm Diseases 0.000 claims description 10
- 125000004432 carbon atom Chemical group C* 0.000 claims description 10
- 125000005843 halogen group Chemical group 0.000 claims description 10
- 229910052739 hydrogen Inorganic materials 0.000 claims description 10
- 229940002612 prodrug Drugs 0.000 claims description 10
- 239000000651 prodrug Substances 0.000 claims description 10
- 125000003118 aryl group Chemical group 0.000 claims description 9
- 201000011510 cancer Diseases 0.000 claims description 8
- 229910052799 carbon Inorganic materials 0.000 claims description 8
- 230000000694 effects Effects 0.000 claims description 8
- 239000001257 hydrogen Substances 0.000 claims description 8
- 229940124597 therapeutic agent Drugs 0.000 claims description 8
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 claims description 7
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 7
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 6
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 6
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 6
- 125000003282 alkyl amino group Chemical group 0.000 claims description 5
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 4
- 125000006619 (C1-C6) dialkylamino group Chemical group 0.000 claims description 4
- 102000052052 Casein Kinase II Human genes 0.000 claims description 4
- 108010010919 Casein Kinase II Proteins 0.000 claims description 4
- 108091000080 Phosphotransferase Proteins 0.000 claims description 4
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 4
- 125000003342 alkenyl group Chemical group 0.000 claims description 4
- 125000003545 alkoxy group Chemical group 0.000 claims description 4
- 125000000304 alkynyl group Chemical group 0.000 claims description 4
- 239000002246 antineoplastic agent Substances 0.000 claims description 4
- 125000004429 atom Chemical group 0.000 claims description 4
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 4
- 125000004663 dialkyl amino group Chemical group 0.000 claims description 4
- 201000010099 disease Diseases 0.000 claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- 201000005787 hematologic cancer Diseases 0.000 claims description 4
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 4
- 230000002401 inhibitory effect Effects 0.000 claims description 4
- 210000004185 liver Anatomy 0.000 claims description 4
- 125000003884 phenylalkyl group Chemical group 0.000 claims description 4
- 102000020233 phosphotransferase Human genes 0.000 claims description 4
- 201000000849 skin cancer Diseases 0.000 claims description 4
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims description 4
- 230000033115 angiogenesis Effects 0.000 claims description 3
- 230000004663 cell proliferation Effects 0.000 claims description 3
- 229940079593 drug Drugs 0.000 claims description 3
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims description 2
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 claims description 2
- 125000006650 (C2-C4) alkynyl group Chemical group 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 claims description 2
- 125000005865 C2-C10alkynyl group Chemical group 0.000 claims description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 2
- 206010009944 Colon cancer Diseases 0.000 claims description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 2
- 206010061218 Inflammation Diseases 0.000 claims description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 206010033128 Ovarian cancer Diseases 0.000 claims description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 206010038389 Renal cancer Diseases 0.000 claims description 2
- 125000005213 alkyl heteroaryl group Chemical group 0.000 claims description 2
- 125000002947 alkylene group Chemical group 0.000 claims description 2
- 210000004369 blood Anatomy 0.000 claims description 2
- 239000008280 blood Substances 0.000 claims description 2
- 210000004556 brain Anatomy 0.000 claims description 2
- 210000000481 breast Anatomy 0.000 claims description 2
- 210000001072 colon Anatomy 0.000 claims description 2
- 125000004122 cyclic group Chemical group 0.000 claims description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 2
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 claims description 2
- 210000003128 head Anatomy 0.000 claims description 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 2
- 201000010235 heart cancer Diseases 0.000 claims description 2
- 208000024348 heart neoplasm Diseases 0.000 claims description 2
- 208000026278 immune system disease Diseases 0.000 claims description 2
- 208000015181 infectious disease Diseases 0.000 claims description 2
- 230000004054 inflammatory process Effects 0.000 claims description 2
- 210000003734 kidney Anatomy 0.000 claims description 2
- 201000010982 kidney cancer Diseases 0.000 claims description 2
- 201000007270 liver cancer Diseases 0.000 claims description 2
- 208000014018 liver neoplasm Diseases 0.000 claims description 2
- 210000004072 lung Anatomy 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 210000001165 lymph node Anatomy 0.000 claims description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
- 208000026037 malignant tumor of neck Diseases 0.000 claims description 2
- 125000002950 monocyclic group Chemical group 0.000 claims description 2
- 210000003739 neck Anatomy 0.000 claims description 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 2
- 210000000496 pancreas Anatomy 0.000 claims description 2
- 201000002528 pancreatic cancer Diseases 0.000 claims description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
- 230000001717 pathogenic effect Effects 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 210000002307 prostate Anatomy 0.000 claims description 2
- 210000003491 skin Anatomy 0.000 claims description 2
- 125000001544 thienyl group Chemical group 0.000 claims description 2
- 208000019553 vascular disease Diseases 0.000 claims description 2
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- 0 CCCCN=C(*C)C(CCCC*C(*)=C(C)C(C)=C)=C(C)I*C(C)CC*C=C(C)N(*)[*+]C Chemical compound CCCCN=C(*C)C(CCCC*C(*)=C(C)C(C)=C)=C(C)I*C(C)CC*C=C(C)N(*)[*+]C 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 230000009707 neogenesis Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US26680109P | 2009-12-04 | 2009-12-04 | |
| US61/266,801 | 2009-12-04 | ||
| US35416510P | 2010-06-11 | 2010-06-11 | |
| US61/354,165 | 2010-06-11 | ||
| PCT/US2010/056712 WO2011068667A1 (en) | 2009-12-04 | 2010-11-15 | Pyrazolopyrimidines and related heterocycles as ck2 inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013512903A JP2013512903A (ja) | 2013-04-18 |
| JP2013512903A5 true JP2013512903A5 (cg-RX-API-DMAC7.html) | 2013-12-19 |
| JP5802676B2 JP5802676B2 (ja) | 2015-10-28 |
Family
ID=44115232
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012542060A Active JP5802676B2 (ja) | 2009-12-04 | 2010-11-15 | Ｃｋ２阻害剤としてのピラゾロピリミジンおよび関連複素環化合物 |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US8575177B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2509602B9 (cg-RX-API-DMAC7.html) |
| JP (1) | JP5802676B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR101851130B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN102762208A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2010326268B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112012013508A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2782684C (cg-RX-API-DMAC7.html) |
| ES (1) | ES2629170T3 (cg-RX-API-DMAC7.html) |
| IL (1) | IL220086B (cg-RX-API-DMAC7.html) |
| PL (1) | PL2509602T3 (cg-RX-API-DMAC7.html) |
| RU (1) | RU2607453C2 (cg-RX-API-DMAC7.html) |
| SG (1) | SG181507A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2011068667A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2555261T3 (es) * | 2010-06-01 | 2015-12-30 | Bayer Intellectual Property Gmbh | Imidazopirazinas sustituidas |
| EP2575818A4 (en) | 2010-06-03 | 2013-11-06 | Pharmacyclics Inc | USE OF BRUTON TYROSINE KINASE INHIBITORS (BTK) |
| WO2012170827A2 (en) * | 2011-06-08 | 2012-12-13 | Cylene Pharmaceuticals, Inc. | Pyrazolopyrimidines and related heterocycles as ck2 inhibitors |
| EP2723746A1 (en) | 2011-06-22 | 2014-04-30 | Vertex Pharmaceuticals Inc. | Compounds useful as inhibitors of atr kinase |
| WO2013161567A1 (ja) * | 2012-04-27 | 2013-10-31 | 新日鐵住金株式会社 | 継目無鋼管及びその製造方法 |
| BR112014032346A2 (pt) | 2012-06-26 | 2017-06-27 | Del Mar Pharmaceuticals | métodos para tratamento de malignidades resistentes ao inibidor de tirosina-quinase em pacientes com polimorfismos genéticos ou desregulações de ahi1 mutações empregando dianidrogalactitol, diacetildianidrogalactitol, dibromodulcitol, ou análogos ou derivados destes |
| TW201414737A (zh) * | 2012-07-13 | 2014-04-16 | 必治妥美雅史谷比公司 | 作爲激酶抑制劑之咪唑并三□甲腈 |
| JP6575950B2 (ja) | 2012-07-24 | 2019-09-18 | ファーマサイクリックス エルエルシー | Ｂｒｕｔｏｎ型チロシンキナーゼ（Ｂｔｋ）阻害剤に対する耐性を伴う変異 |
| EP4534538A3 (en) | 2012-12-07 | 2025-06-11 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
| CA2897200C (en) | 2013-01-14 | 2021-07-06 | Incyte Corporation | Bicyclic aromatic carboxamide compounds useful as pim kinase inhibitors |
| AR094664A1 (es) | 2013-01-15 | 2015-08-19 | Incyte Corp | Compuestos de tiazolcarboxamidas y piridinacarboxamida utiles como inhibidores de quinasa pim |
| WO2014143240A1 (en) | 2013-03-15 | 2014-09-18 | Vertex Pharmaceuticals Incorporated | Fused pyrazolopyrimidine derivatives useful as inhibitors of atr kinase |
| US8969360B2 (en) | 2013-03-15 | 2015-03-03 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
| WO2014143241A1 (en) | 2013-03-15 | 2014-09-18 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
| JP2016519684A (ja) | 2013-04-08 | 2016-07-07 | デニス エム ブラウン | 準最適に投与された薬物療法の有効性を改善するための及び／又は副作用を低減するための方法および組成物 |
| CN103360399B (zh) * | 2013-08-02 | 2016-03-02 | 北京大学 | 6-芳基取代-咪唑-[1,2-b]哒嗪类衍生物，其制备方法及用途 |
| US9556197B2 (en) | 2013-08-23 | 2017-01-31 | Incyte Corporation | Furo- and thieno-pyridine carboxamide compounds useful as pim kinase inhibitors |
| CN103570728B (zh) * | 2013-11-12 | 2015-12-30 | 山东大学 | 一种取代吡唑并[1,5-a]嘧啶类衍生物及其制备方法与应用 |
| CA2932757C (en) | 2013-12-06 | 2023-10-31 | Vertex Pharmaceuticals Incorporated | 2-amino-6-fluoro-n-[5-fluoro-pyridin-3-yl]pyrazolo[1,5-a]pyrimidin-3-carboxamide compound useful as atr kinase inhibitor, its preparation, different solid forms and radiolabelled derivatives thereof |
| ES2702126T3 (es) * | 2013-12-10 | 2019-02-27 | Bristol Myers Squibb Co | Compuestos de imidazopiridazina útiles como moduladores de respuestas a IL-12, IL-23 y/o IFN alfa |
| TWI534148B (zh) * | 2014-02-13 | 2016-05-21 | 生華生物科技股份有限公司 | 吡唑並嘧啶前藥及其使用方法 |
| GB201403093D0 (en) * | 2014-02-21 | 2014-04-09 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
| CN106170489B (zh) * | 2014-05-28 | 2019-05-03 | 诺华股份有限公司 | 新的吡唑并嘧啶衍生物及其作为malt1抑制剂的用途 |
| RU2719583C2 (ru) | 2014-06-05 | 2020-04-21 | Вертекс Фармасьютикалз Инкорпорейтед | Радиоактивно меченные производные 2-амино-6-фтор-n-[5-фтор-пиридин-3-ил]-пиразоло[1, 5-а]пиримидин-3-карбоксамида, используемые в качестве ингибитора atr киназы, препараты на основе этого соединения и его различные твердые формы |
| SG11201610500WA (en) | 2014-06-17 | 2017-01-27 | Vertex Pharma | Method for treating cancer using a combination of chk1 and atr inhibitors |
| US9822124B2 (en) | 2014-07-14 | 2017-11-21 | Incyte Corporation | Bicyclic heteroaromatic carboxamide compounds useful as Pim kinase inhibitors |
| US9580418B2 (en) | 2014-07-14 | 2017-02-28 | Incyte Corporation | Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors |
| CN105457029A (zh) * | 2014-09-29 | 2016-04-06 | 中国科学院上海巴斯德研究所 | 抑制酪蛋白激酶2活性在促进i型干扰素表达的应用 |
| JP2017537940A (ja) * | 2014-12-10 | 2017-12-21 | マサチューセッツ インスティテュート オブ テクノロジー | 増殖性疾患の処置に有用な融合１，３−アゾール誘導体 |
| CA2973432C (en) * | 2015-01-23 | 2023-04-04 | Glaxosmithkline Intellectual Property Development Limited | Pyrazolo[3,4-d]pyrimidin derivative and its use for the treatment of leishmaniasis |
| US9540347B2 (en) | 2015-05-29 | 2017-01-10 | Incyte Corporation | Pyridineamine compounds useful as Pim kinase inhibitors |
| AR105967A1 (es) | 2015-09-09 | 2017-11-29 | Incyte Corp | Sales de un inhibidor de pim quinasa |
| KR102678021B1 (ko) | 2015-09-30 | 2024-06-26 | 버텍스 파마슈티칼스 인코포레이티드 | Dna 손상제와 병용되는, atr 저해제를 포함하는 암 치료용 약제학적 조성물 |
| TW201718546A (zh) | 2015-10-02 | 2017-06-01 | 英塞特公司 | 適用作pim激酶抑制劑之雜環化合物 |
| KR20180107261A (ko) | 2016-02-16 | 2018-10-01 | 메사추세츠 인스티튜트 오브 테크놀로지 | Myc 조정제로서의 MAX 결합제 및 그의 용도 |
| CN109562111B (zh) * | 2016-06-24 | 2023-04-04 | 北极星药业股份有限公司 | Ck2抑制剂，其组合物及方法 |
| AU2018256459B2 (en) | 2017-04-21 | 2023-12-07 | Ikena Oncology, Inc. | Indole AHR inhibitors and uses thereof |
| CN107188901A (zh) * | 2017-05-27 | 2017-09-22 | 无锡捷化医药科技有限公司 | 一种(3‑(3‑(二甲氨基)丙氧基)苯基)硼酸的制备方法 |
| BR112020001278A2 (pt) | 2017-07-28 | 2020-07-21 | Yuhan Corporation | processo aprimorado para preparar derivados de aminopirimidina |
| EP3658557B1 (en) | 2017-07-28 | 2024-06-05 | Takeda Pharmaceutical Company Limited | Tyk2 inhibitors and uses thereof |
| GB201715194D0 (en) | 2017-09-20 | 2017-11-01 | Carrick Therapeutics Ltd | Compounds and their therapeutic use |
| AR113922A1 (es) | 2017-12-08 | 2020-07-01 | Incyte Corp | Terapia de combinación de dosis baja para el tratamiento de neoplasias mieloproliferativas |
| US11071727B2 (en) | 2018-01-26 | 2021-07-27 | Northwestern University | Therapeutic targeting of proteolytic cleavage of the mixed lineage leukemia gene product (MLL1) by taspase1 using kinase inhibitors |
| JP7385658B2 (ja) | 2018-10-30 | 2023-11-22 | クロノス バイオ インコーポレイテッド | Ｃｄｋ９活性を調節するための化合物、組成物、および方法 |
| CN112500416B (zh) * | 2019-07-30 | 2021-12-17 | 厦门宝太生物科技股份有限公司 | 一种吡唑并三嗪类化合物中间体的制备方法 |
| EP4065582B1 (en) | 2019-11-26 | 2025-02-19 | Ikena Oncology, Inc. | Polymorphic carbazole derivatives and uses thereof |
| GB201918541D0 (en) | 2019-12-16 | 2020-01-29 | Carrick Therapeutics Ltd | Therapeutic compounds and their use |
| KR102337404B1 (ko) * | 2020-01-03 | 2021-12-10 | 연세대학교 산학협력단 | 조직 재생용 조성물 |
| JP2023520883A (ja) * | 2020-03-30 | 2023-05-22 | センホア・バイオサイエンシーズ・インコーポレイテッド | Ｒｎａウイルス感染症、特にｃｏｖｉｄ－１９を処置するための抗ウイルス化合物および方法 |
| CN116323569A (zh) * | 2020-09-15 | 2023-06-23 | 田边三菱制药株式会社 | 三嗪化合物的盐、其晶型及制造方法 |
| CA3172939A1 (en) * | 2021-01-09 | 2022-07-14 | Bugworks Research, Inc. | Diaminopyrazolo[1,5-a]pyrimidine-6-carbonitrile compounds as adenosine 2a receptor and adenosine 2b receptor antagonist |
| US12343421B2 (en) * | 2021-11-01 | 2025-07-01 | Solaana MD LLC | Vitamin D base layer |
| WO2024187126A1 (en) * | 2023-03-09 | 2024-09-12 | Aquinnah Pharmaceuticals, Inc. | Inhibitors of tdp-43 and tau aggregation |
| US12269826B1 (en) * | 2023-11-16 | 2025-04-08 | King Faisal University | 7H-pyrido[4′,3′:4,5]pyrrolo[2,3-c][1,7]naphthyridine compounds as CK2 inhibitors |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5624677A (en) | 1995-06-13 | 1997-04-29 | Pentech Pharmaceuticals, Inc. | Controlled release of drugs delivered by sublingual or buccal administration |
| TW438587B (en) * | 1995-06-20 | 2001-06-07 | Takeda Chemical Industries Ltd | A pharmaceutical composition for prophylaxis and treatment of diabetes |
| US7071218B2 (en) * | 2001-11-15 | 2006-07-04 | Incyte San Diego Incorporated | N-substituted heterocycles for the treatment of hypercholesteremia, dyslipidemia and other metabolic disorders; cancer, and other diseases |
| US7206308B2 (en) * | 2001-12-22 | 2007-04-17 | International Business Machines Corporation | Method of providing a non-blocking routing network |
| JP2005530739A (ja) * | 2002-04-19 | 2005-10-13 | セルラー ジェノミクス，インコーポレーテッド | イミダゾ［１，２−ａ］ピラジン−８−イルアミン、生成方法、および使用方法 |
| WO2004006916A1 (en) * | 2002-07-10 | 2004-01-22 | Applied Research Systems Ars Holding Nv | Use of compounds for increasing spermatozoa motility |
| PL374718A1 (en) * | 2002-07-10 | 2005-10-31 | Applied Research Systems Ars Holding N.V. | Azolidinone-vinyl fused-benzene derivatives |
| US7205308B2 (en) * | 2002-09-04 | 2007-04-17 | Schering Corporation | Trisubstituted 7-aminopyrazolopyrimidines as cyclin dependent kinase inhibitors |
| CA2497544C (en) * | 2002-09-04 | 2010-11-02 | Schering Corporation | Pyrazolo[1,5-a]pyrimidines compounds as cyclin dependent kinase inhibitors |
| AU2003225669A1 (en) * | 2002-09-26 | 2004-04-19 | Pintex Pharmaceuticals, Inc. | Pin1-modulating compounds and methods of use thereof |
| MXPA05008955A (es) * | 2003-02-28 | 2006-02-22 | Teijin Pharma Ltd | Derivados de pirazolo [1,5-a] pirimidina. |
| PE20051128A1 (es) * | 2004-02-25 | 2006-01-16 | Schering Corp | Pirazolotriazinas como inhibidores de quinasa |
| US7842698B2 (en) * | 2004-09-03 | 2010-11-30 | Merck Serono S.A. | Pyridine methylene azolidinones and use thereof phosphoinositide inhibitors |
| EP2046333A4 (en) * | 2006-07-24 | 2010-09-15 | Glaxosmithkline Llc | THIOZOLIDINEDIONE DERIVATIVES AS INHIBITORS OF P13-KINASE |
| FR2907120B1 (fr) * | 2006-10-12 | 2013-01-11 | Sanofi Aventis | Nouveaux derives imidazolones,leur preparation a titre de medicaments,compositions pharmaceutiques,utilisation comme inhibiteurs de proteines kinases notamment cdc7 |
| CN101981033B (zh) * | 2008-02-06 | 2015-02-04 | 百时美施贵宝公司 | 用作激酶抑制剂的取代的咪唑并哒嗪化合物 |
| MX2011012369A (es) * | 2009-05-20 | 2012-03-16 | Cylene Pharmaceuticals Inc | Pirazolopirimidinas y heterociclos relacionados como inhibidores de cinasa. |
-
2010
- 2010-11-15 SG SG2012041034A patent/SG181507A1/en unknown
- 2010-11-15 RU RU2012127792A patent/RU2607453C2/ru active
- 2010-11-15 KR KR1020127017450A patent/KR101851130B1/ko active Active
- 2010-11-15 CN CN2010800630542A patent/CN102762208A/zh active Pending
- 2010-11-15 US US12/946,759 patent/US8575177B2/en active Active
- 2010-11-15 BR BR112012013508A patent/BR112012013508A2/pt not_active IP Right Cessation
- 2010-11-15 AU AU2010326268A patent/AU2010326268B2/en active Active
- 2010-11-15 PL PL10834934T patent/PL2509602T3/pl unknown
- 2010-11-15 JP JP2012542060A patent/JP5802676B2/ja active Active
- 2010-11-15 ES ES10834934.1T patent/ES2629170T3/es active Active
- 2010-11-15 EP EP10834934.1A patent/EP2509602B9/en active Active
- 2010-11-15 WO PCT/US2010/056712 patent/WO2011068667A1/en not_active Ceased
- 2010-11-15 CA CA2782684A patent/CA2782684C/en active Active
-
2012
- 2012-05-31 IL IL220086A patent/IL220086B/en active IP Right Grant
-
2013
- 2013-09-13 US US14/026,591 patent/US9303033B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013512903A5 (cg-RX-API-DMAC7.html) | ||
| RU2012127792A (ru) | Пиразолопиримидины и родственные гетероциклы как ск2 ингибиторы | |
| ES2660831T3 (es) | Derivados de imidazol condensados útiles como inhibidores de IDO | |
| JP2016517857A5 (cg-RX-API-DMAC7.html) | ||
| JP2017511360A5 (cg-RX-API-DMAC7.html) | ||
| JP2016513737A5 (cg-RX-API-DMAC7.html) | ||
| RU2015118647A (ru) | Аминопиримидиновые соединения в качестве ингибиторов содержащих т790м мутантных egfr | |
| JP2014500295A5 (cg-RX-API-DMAC7.html) | ||
| JP2015506348A5 (cg-RX-API-DMAC7.html) | ||
| JP2010523522A5 (cg-RX-API-DMAC7.html) | ||
| JP2017528498A5 (cg-RX-API-DMAC7.html) | ||
| JP2016509047A5 (cg-RX-API-DMAC7.html) | ||
| HUE031367T2 (en) | A pharmaceutical combination comprising an Hsp 90 inhibitor and a mTOR inhibitor | |
| JP2016513661A5 (cg-RX-API-DMAC7.html) | ||
| JP2007529421A5 (cg-RX-API-DMAC7.html) | ||
| RU2018127728A (ru) | Слитые трициклические гетероциклические соединения в качестве ингибиторов интегразы вич | |
| JP2017508782A5 (cg-RX-API-DMAC7.html) | ||
| RU2016131189A (ru) | ПРОИЗВОДНЫЕ ПИРРОЛО[3,2-d]ПИРИМИДИНА В КАЧЕСТВЕ ИНДУКТОРОВ ЧЕЛОВЕЧЕСКОГО ИНТЕРФЕРОНА | |
| UA114177C2 (uk) | ЗАСТОСУВАННЯ ЗАМІЩЕНИХ 2,3-ДИГІДРОІМІДАЗО[1,2-c]ХІНАЗОЛІНІВ | |
| WO2018152548A4 (en) | Selective inhibitors of protein arginine methyltransferase 5 (prmt5) | |
| JP2016513696A5 (cg-RX-API-DMAC7.html) | ||
| JP2016525104A5 (cg-RX-API-DMAC7.html) | ||
| JP2018502101A5 (cg-RX-API-DMAC7.html) | ||
| RU2015121037A (ru) | Производные фенилэтилпиридина в качестве ингибиторов pde-4 | |
| RU2012130929A (ru) | Гетероциклические соединения в качестве ингибиторов янус-киназы |